Edurne Mugarza

Scientific project manager at @VHIO. Previous postdoc at @UCLA. Ex-@TheCrick #DownwardLab member. Obsessed with cancer immunology and immunotherapy.

[The Francis Crick Institute @TheCrick]

"Lung cancer is one of the hardest types of cancer to treat, so working out how to harness the immune system to better target tumours is so important."

Read about the new work from Megan Cole, @JulianDownward, @F_vanMaldegem and more ⤵️ https://t.co/Jptua5kIXH

[The Francis Crick Institute @TheCrick]

Research from @JulianDownward @Anastap78 and @molina_arcas at the Crick, working with Revolution Medicines, shows that combining treatments can help to eradicate lung tumours in mice.

Read the full story ⤵️
https://t.co/NqEGLHosk9

[Pancho Barriga @barrigafm]

We have an open postdoc position in my group! The projects of the lab are focused on understanding how cancer genomes dictate immune responses, tumor evolution, and therapy resistance. Come join us in a great environment!
https://t.co/d2BVbNG8XX

[Joaquin Mateo @quimmateo]

#hiring #cancerresearch we have 2 open positions for technicians in the lab @VHIO #Barcelona, one to work on NGS assays and the other one to work with our PDX collection and in-vivo experiments. Starting date ASAP. https://t.co/m5YsCOAwC6

From https://t.co/9ZaQGhkZuh📷

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

📣 Become a versatile and efficient scientific manager with the new Master's in Health and Science Management, a joint initiative between @UABBarcelona @biocienciesuab & VHIO.

For more information  ➡️ https://t.co/q0eaVfPo5C

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

📣 Become a versatile and efficient scientific manager with the new Master's in Health and Science Management, a joint initiative between @UABBarcelona @biocienciesuab & VHIO.

For more information  ➡️ https://t.co/q0eaVfPo5C

[Miriam Molina Arcas @molina_arcas]

Our in vivo crispr screen paper is finally out in this issue of @CR_AACR

[Febe van Maldegem @F_vanMaldegem]

We are recruiting for 3 PhD student positions, investigating different aspects of the lung cancer tumour microenvironment, within the context of an exciting EU collaboration! Great facilities & great teams! 🔬
https://t.co/VGvZ7vQTcN

Apply before 6th July!

[Miriam Molina Arcas @molina_arcas]

Fantastic opportunity to join the #downwardlab! Great science with amazing people. I couldn’t recommend it more (a bit biased here). Please share!

[Febe van Maldegem @F_vanMaldegem]

Local T cell neighbourhoods determine outcome in non-small cell lung cancer treatment with KRAS-G12C inhibitors.

Timely and relevant work from Megan Cole and @Anastap78 from the @JulianDownwardlab, and @claudialee_ from the @SwantonLab.
https://t.co/9MXgB8ImS1

[Miriam Molina Arcas @molina_arcas]

Happy to share our review published in @Cancer_Cell. We provide an update on RAS inhibitor development, discuss the rationale for combining #KRAS inhibitors with immunotherapies, and address challenges and future directions. @JulianDownward @TheCrick https://t.co/jYqT7WgOBL

[Edurne Mugarza @EdurMugarza]

@SareenaRana Thanks Sareeny!! ❤️

[Edurne Mugarza @EdurMugarza]

Super excited to share the first paper from the Puig Saus lab! We have developed a new CAR-T cell therapy for melanoma and are currently working on the clinical translation, exciting times ahead! https://t.co/YFzSGaswYN

[Parker Institute for Cancer Immunotherapy @parkerici]

Scientists at @UCLAHealth, supported by PICI, have developed new CAR T-cell therapy targeting cutaneous and rare melanoma subtypes. Led by Parker Senior Fellow @PuigSaus, the research published in @NatureComms harnessed engineered immune cells to target TYRP1 protein. (1/2)

[Edurne Mugarza @EdurMugarza]

@sdecarne Thanks Sophie! ❤️ Hope all is well in London

[Edurne Mugarza @EdurMugarza]

@Aliciaadv @TheCrick @JulianDownward Woohoo!! Congrats Alicia!! 🥳

[Edurne Mugarza @EdurMugarza]

Another preprint from the #Downwardlab! Combining RAS G12C(ON) and SHP2 inhibition sensitizes immune cold lung tumors to PD1 inhibition. Great work by @Anastap78 and co.!

[Miriam Molina Arcas @molina_arcas]

Our last preprint is now online #Downwardlab ⁦@JulianDownward⁩. Combining RAS G12C(ON) and SHP2 inhibitors we sensitise anti-PD1 refractory tumours to immune checkpoint blockade. Led by the talented ⁦@Anastap78⁩ https://t.co/cfyM8qKdvy

[bioRxiv Cancer Bio @biorxiv_cancer]

Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a ... https://t.co/xyOvDOWRVs #biorxiv_cancer

[Edurne Mugarza @EdurMugarza]

Check out this opportunity to do a PhD in the best lab in the world! (Ok, I might be a bit biased...)

[Julian Downward @JulianDownward]

Fantastic PhD programme positions open at the Francis Crick Institute, including one in my lab.

[Miriam Molina Arcas @molina_arcas]

Excited to share our review about Facts and hopes of combining KRAS inhibitors and immunotherapies #openaccess in @CCR_AACR with ⁦@jboumelha⁩ and ⁦@JulianDownward⁩ at ⁦@TheCrick⁩ https://t.co/fpCHISqelY

[Jesse Boumelha @jboumelha]

Excited to share our new review in @CCR_AACR discussing current knowledge and future hopes for combing cancer immunotherapy with KRAS inhibitors

https://t.co/JdWf0LWlJ9